Trial reportJournal of studies on alcohol and drugs2014
The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.
Trial report in Journal of studies on alcohol and drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Single state agency licensure requirements for substance use disorder treatment programs in the United States: results of a national survey.Substance abuse treatment, prevention, and policy · 2026Article
- A scoping review of interventions addressing social determinants of health and their influence on opioid use disorder outcomes.Drug and alcohol dependence · 2025Article
- Not in my treatment center: Leadership's perception of barriers to MOUD adoption.Journal of substance abuse treatment · 2023Article
- Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.The journal of behavioral health services & research · 2020Article
- The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.Journal of substance abuse treatment · 2020Article
- Prevention, screening, and treatment for heavy drinking and alcohol use disorder.The lancet. Psychiatry · 2019Review
- Access to Addiction Pharmacotherapy in Private Health Plans.Journal of substance abuse treatment · 2016Article
- Medicaid, Private Insurance, and the Availability of Smoking Cessation Interventions in Substance Use Disorder Treatment.Psychiatric services (Washington, D.C.) · 2015Article
- Comparing rating paradigms for evidence-based program registers in behavioral health: evidentiary criteria and implications for assessing programs.Evaluation and program planning · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveMedications for the treatment of substance use disorders (SUDs) are not widely available in publicly funded SUD treatment programs. Few studies have drawn on longitudinal data to examine the organizational characteristics associated with programs transitioning from not delivering any pharmacotherapy to adopting at least one SUD medication.
methodUsing two waves of panel longitudinal data collected over a 5-year period, we measured the transition to medication adoption in a cohort of 190 publicly funded treatment organizations that offered no SUD medications at baseline. Independent variables included organizational characteristics, medical resources, funding, treatment culture, and detailing activities by pharmaceutical companies.
resultsOf 190 programs not offering SUD pharmacotherapy at baseline, 22.6% transitioned to offering at least one SUD medication at follow-up approximately 5 years later. Multivariate logistic regression results indicated that the employment of at least one physician at baseline, having a greater proportion of Medicaid clients, and pharmaceutical detailing were positively associated with medication adoption.
conclusionsAdoption of pharmacotherapy was more likely in programs that had greater medical resources, Medicaid funding, and contact with pharmaceutical companies. Given the potential expansion of Medicaid under the Affordable Care Act, patients served by publicly funded programs may gain greater access to such treatments, but research is needed to document health reform's impact on this sector of the treatment system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.